Introduction
Human immunodeficiency virus (HIV) is a lentivirus that infects the human immune system, primarily targeting CD4+ T lymphocytes, macrophages, and dendritic cells. Since its identification in the early 1980s, HIV has become a global public health issue, causing an estimated 38 million people worldwide to live with the infection and 1.7 million deaths annually. The virus is transmitted through the exchange of bodily fluids and has a complex life cycle that includes reverse transcription, integration into the host genome, and extensive genetic diversity. The availability of antiretroviral therapy (ART) has transformed HIV from an acute fatal disease into a chronic, manageable condition for many patients, yet challenges remain in prevention, access to care, and eradication efforts.
History and Discovery
Early Observations and Clinical Presentation
In the late 1970s and early 1980s, clinicians reported a series of previously uncommon conditions among young men, including severe infections, lymphadenopathy, and wasting syndrome. These presentations clustered under the term acquired immunodeficiency syndrome (AIDS) and were distinguished by a marked decline in CD4+ cell counts. Early investigations focused on identifying a causal agent, and a small group of laboratories isolated a retrovirus from patient samples. The discovery, announced in 1983, identified the etiologic agent of AIDS as a retrovirus, later named HIV, and established a foundation for virological and immunological research.
Isolation of the Virus and Early Studies
The first successful isolation of HIV involved culturing patient lymphocytes in the presence of a human immunodeficiency factor and detecting viral replication through cytopathic effect and reverse transcriptase activity. Subsequent serological tests, such as enzyme-linked immunosorbent assays (ELISA), were developed to detect anti-HIV antibodies in plasma. These assays facilitated large-scale screening and epidemiological surveillance. The early era of HIV research also witnessed the characterization of the virus's genetic structure, revealing two main groups - Group M (major) and Group O (outlier) - and a range of subtypes (A, B, C, D, F, G, H, J, K) that differ in geographic prevalence and transmission dynamics.
Virology and Molecular Biology
Genome Organization and Protein Products
HIV is a positive-sense, single-stranded RNA virus with a genome of approximately 9.7 kilobases. The viral genome encodes two pol genes (gag, pol, env) and regulatory regions (tat, rev, nef, vpu, vpr, vif). The gag polyprotein gives rise to core and structural proteins, including capsid, matrix, and nucleocapsid. Pol encodes enzymes reverse transcriptase, integrase, and protease, essential for viral replication. Env produces the surface glycoprotein gp120 and transmembrane gp41, mediating attachment and fusion with host cells. Regulatory proteins modulate viral transcription, immune evasion, and cytotoxicity. The high mutation rate during reverse transcription contributes to viral diversity and drug resistance.
Life Cycle and Host Interaction
HIV initiates infection by binding gp120 to the CD4 receptor on target cells, followed by coreceptor engagement (CCR5 or CXCR4). This triggers gp41-mediated fusion of viral and cellular membranes, releasing the nucleocapsid into the cytoplasm. Reverse transcriptase converts the viral RNA genome into double-stranded DNA, which integrase incorporates into the host chromosomal DNA. The proviral DNA serves as a template for transcription of viral mRNAs, which are exported to the cytoplasm and translated into proteins. Newly synthesized virions are assembled at the plasma membrane, acquire an envelope from the host cell, and are released by budding. The cycle can persist in latent reservoirs within resting CD4+ T cells, complicating eradication efforts.
Epidemiology and Transmission
Modes of Transmission
HIV transmission occurs primarily through exposure to infected blood, semen, vaginal secretions, rectal fluids, and breast milk. Sexual contact, especially unprotected anal intercourse, remains the most common route worldwide. Parenteral exposure through contaminated needles, shared injection equipment, and blood transfusions account for significant transmission in certain regions. Mother-to-child transmission can occur during pregnancy, labor, delivery, or breastfeeding. Occasional transmission via dental procedures or organ transplantation has been documented, highlighting the importance of screening and sterilization protocols.
Geographic Distribution and Trends
Globally, HIV prevalence exhibits substantial geographic variation. Sub-Saharan Africa remains the epicenter, with over 70% of new infections occurring in the region. In the United States, prevalence is concentrated in specific demographic groups, including men who have sex with men, people who inject drugs, and African American communities. In contrast, many European and Asian countries report lower prevalence, though pockets of high incidence exist. Recent data indicate that incidence rates in several high-income countries have plateaued or declined, largely due to widespread ART and prevention initiatives, whereas some low- and middle-income countries continue to experience rising infection rates.
Risk Groups and Demographic Patterns
Key risk factors for HIV acquisition include unprotected sexual activity, multiple sexual partners, concurrent sexually transmitted infections, and engagement in commercial sex work. Injection drug use, especially sharing needles, is a high-risk activity that promotes parenteral transmission. Behavioral, social, and structural factors - such as stigma, gender inequality, poverty, and limited access to health services - interact to influence transmission dynamics. Certain populations, such as adolescents, sex workers, transgender individuals, and prisoners, face heightened vulnerability due to compounded risk factors and barriers to care.
Clinical Course and Pathogenesis
Acute Retroviral Syndrome
Following initial infection, individuals may experience a prodromal phase lasting 2–4 weeks, characterized by fever, lymphadenopathy, pharyngitis, rash, and myalgias. This acute retroviral syndrome results from a rapid surge in viral replication and a robust innate immune response. While symptoms may resolve spontaneously, the event marks the establishment of a latent reservoir and a decline in CD4+ cell counts. Seroconversion to detectable antibodies typically occurs within 6–12 weeks of exposure, providing a diagnostic window for early detection.
Chronic Infection and AIDS Development
In the asymptomatic phase, HIV persists at low levels while gradually depleting CD4+ T cells. Without treatment, progression to AIDS - defined by a CD4+ count below 200 cells/µL or the occurrence of an AIDS-defining illness - occurs within 7–10 years on average. During this stage, immune dysfunction allows opportunistic pathogens to establish infection, leading to serious clinical complications. ART initiation is recommended as soon as possible to preserve immune function, prevent disease progression, and reduce transmission risk.
Common Opportunistic Infections and Neoplasms
Immunosuppression in HIV-infected individuals predisposes to a spectrum of opportunistic infections, including Pneumocystis jirovecii pneumonia, cytomegalovirus retinitis, cryptococcal meningitis, Mycobacterium avium complex disease, and disseminated Mycobacterium tuberculosis. Bacterial infections such as bacterial meningitis and urinary tract infections also occur more frequently. Neoplasms commonly associated with HIV include Kaposi sarcoma, invasive cervical cancer, anal squamous cell carcinoma, and non-Hodgkin lymphoma. Prophylactic strategies - such as pneumocystis prophylaxis and screening for tuberculosis - are integral components of comprehensive HIV care.
Diagnosis and Monitoring
Screening Algorithms
Initial screening for HIV employs enzyme immunoassays (EIAs) or fourth-generation ELISA kits that detect both antibodies and p24 antigen. Positive screening results require confirmation by a supplemental assay, typically a Western blot or an immunofluorescence assay. Rapid diagnostic tests (RDTs) allow point-of-care screening, providing results within 15–20 minutes and facilitating immediate counseling. High-throughput testing platforms and sample pooling strategies are used in resource-limited settings to optimize testing coverage while conserving reagents.
Confirmatory Testing and Resistance Evaluation
Confirmatory testing involves nucleic acid amplification techniques (NAATs) to detect viral RNA or proviral DNA. Quantitative viral load assays measure plasma HIV RNA levels, expressed as copies/mL, and are critical for assessing treatment efficacy. Resistance testing, performed through sequencing of the pol gene, identifies mutations conferring resistance to specific antiretroviral agents. This information guides regimen selection and helps clinicians adapt therapy in the event of virologic failure.
Monitoring and Treatment Response
Routine clinical monitoring includes measurement of CD4+ cell counts and viral load at baseline and every 3–6 months following ART initiation. Sustained viral suppression - defined as an undetectable viral load (
Therapeutic Management
Antiretroviral Therapy Regimens
First-line ART typically consists of two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor. Current guidelines recommend a tenofovir-based backbone with either efavirenz, dolutegravir, or bictegravir. Regimens are chosen based on drug resistance profiles, comorbidities, potential drug interactions, and patient preference. Long-acting injectable formulations and fixed-dose combinations have improved adherence by reducing dosing frequency and pill burden.
Pharmacologic Classes and Mechanisms
HIV antiretroviral agents target distinct stages of the viral life cycle. NRTIs mimic natural nucleosides and terminate reverse transcriptase activity. NNRTIs bind an allosteric pocket on reverse transcriptase, causing conformational changes that inhibit catalysis. Protease inhibitors prevent maturation of viral proteins, leading to non-infectious virions. Integrase strand transfer inhibitors (INSTIs) block integration of viral DNA into the host genome. Newer agents, such as capsid inhibitors and latency-reversing agents, are being investigated for their potential to target residual viral reservoirs.
Adherence and Resistance Management
Adherence to ART is critical for achieving viral suppression and preventing resistance. Non-adherence can arise from side effects, pill fatigue, psychosocial barriers, and structural obstacles. Strategies to improve adherence include patient education, adherence counseling, mobile health interventions, and support groups. When virologic failure occurs, resistance testing informs regimen modification. Switching to regimens with high genetic barriers to resistance, such as INSTI-based therapies, is common practice. In cases of extensive resistance, clinicians may incorporate newer agents or combinations tailored to the resistance profile.
Prevention and Public Health Interventions
Barrier Methods and Risk Reduction
Barrier protection - primarily condoms - remains a cornerstone of HIV prevention. Consistent condom use during all forms of sexual activity significantly reduces transmission risk. Needle and syringe programs, as well as safe injection counseling, provide critical services for people who inject drugs. Pre‑exposure prophylaxis (PrEP) using daily tenofovir disoproxil fumarate/emtricitabine has been demonstrated to reduce acquisition risk by up to 90% among high-risk populations when taken consistently. Community-based testing, education, and destigmatization campaigns also contribute to early detection and linkage to care.
PrEP, PEP, and TasP Strategies
PrEP is recommended for individuals at substantial risk of exposure, including serodiscordant couples and men who have sex with men. Post‑exposure prophylaxis (PEP) involves a 28‑day course of ART initiated within 72 hours of potential exposure. Treatment as prevention (TasP) acknowledges that virally suppressed individuals have a negligible probability of transmitting the virus. Implementation of these strategies requires comprehensive adherence support, regular monitoring, and the integration of behavioral interventions to address underlying risk factors.
Public Health Policy and Social Dimensions
International Funding and Programmatic Responses
The Global Fund to Fight AIDS, Tuberculosis and Malaria and the United Nations Programme on HIV/AIDS (UNAIDS) have mobilized substantial resources toward testing, treatment, and prevention. In many low- and middle-income countries, donor-funded programs have scaled up ART coverage, expanded diagnostic services, and established community-based support networks. Policy frameworks promoting universal health coverage aim to reduce disparities in access. However, funding gaps persist, particularly in regions with weak health systems and ongoing conflict, underscoring the need for sustained financial commitment.
Stigma, Discrimination, and Human Rights
Social stigma and discrimination remain significant barriers to HIV testing, treatment initiation, and retention. Homophobia, transphobia, and gender discrimination can deter individuals from seeking care. Human rights violations - such as non-consensual testing, criminalization of same-sex relationships, and coerced disclosure - contribute to treatment delays and suboptimal outcomes. Addressing these challenges requires community engagement, legal reform, and targeted education campaigns to foster an environment where individuals feel empowered to seek and receive care.
Legal Frameworks and Ethical Considerations
Legal mandates for HIV testing and disclosure vary widely. Some jurisdictions require testing of certain populations (e.g., prenatal, inmates, prisoners), while others impose strict confidentiality protections. Ethical issues arise concerning informed consent, disclosure of status, and allocation of limited resources. The principle of “no discrimination” underpins international human rights frameworks, yet enforcement remains uneven. Ongoing dialogue among policymakers, clinicians, and civil society organizations is essential to reconcile public health objectives with individual rights.
Current Research and Future Prospects
Vaccine Development Efforts
Vaccine research focuses on eliciting broadly neutralizing antibodies (bNAbs) and T‑cell responses that can prevent or control infection. Candidate strategies include recombinant protein subunits, viral vectors, and DNA-based vaccines, often delivered in prime‑boost regimens. The RV144 trial in Thailand demonstrated modest efficacy (~31%) using a canarypox vector prime and recombinant gp120 boost, inspiring subsequent studies. Recent trials incorporating mosaic antigens and CRISPR-based gene editing aim to address viral diversity and immune escape. Despite progress, an effective, widely deployable vaccine remains elusive.
Gene Editing, Eradication, and Cure Attempts
Interventions targeting viral reservoirs involve gene editing technologies such as CRISPR‑Cas9 to excise proviral DNA or disrupt host genes essential for viral entry (e.g., CCR5). Gene therapy approaches also explore insertion of anti‑HIV constructs into patient genomes. Early-phase clinical trials have reported safety and potential reductions in viral load. However, challenges include off-target effects, delivery efficiency, and the persistence of latent reservoirs. Parallel research explores immunotherapeutic strategies, such as therapeutic vaccination and immune checkpoint blockade, to restore immune surveillance of infected cells.
Emerging Diagnostic and Monitoring Technologies
Advancements in point-of-care testing now enable rapid viral load measurement in resource-limited settings, using microfluidic platforms and smartphone-based readouts. Longitudinal monitoring of resistance mutations through next-generation sequencing facilitates personalized therapy adjustments. Biomarkers such as soluble CD14 and T cell activation markers provide insight into residual immune activation under ART. Additionally, novel assays for detecting residual viremia, including digital droplet PCR and single-copy assays, enhance the understanding of viral persistence and guide eradication strategies.
See also
- HIV treatment
- Antiretroviral therapy
- Acquired immunodeficiency syndrome
- Pre‑exposure prophylaxis
No comments yet. Be the first to comment!